TrovaGene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections

SAN DIEGO, May 10, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

This patent pertains to the detection of pathogenic infections from urine specimens and complements previously issued U.S. patents, including the reissued patent RE39920 for the detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples. Other previously issued, related patents include EP0920539 for detection of fetal nucleic acids from maternal urine, and EP1634966 for detection of cancer-specific nucleic acids from a patient's urine sample.

"This patent is a valuable addition to our fundamental IP portfolio," said Dr. Antonius Schuh, chief executive officer of Trovagene. "It provides a basis for diagnosing and monitoring viral, bacterial or parasitic infections using a sample that is stable, easy to collect, and truly non-invasive. This provides a convenient method for sample collection anywhere in the world, whether in industrialized or developing countries."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.